Herantis Pharma – executive interview

Herantis Pharma – executive interview

Herantis Pharma — 4 videos in collection

More on this equity

In this interview, we speak to Antti Vuolanto, CEO of Herantis Pharma, and Henri Huttunen, the company’s CSO. We discuss the latest developments for lead asset HER-096, including the Phase Ib trial readout, the supplementary biomarker programme outcomes and plans for a subsequent Phase II trial. We also cover the company’s latest fundraises as well as key upcoming potential catalysts and milestones for investors to watch out for.

Herantis Pharma is a Finland-based clinical-stage biotechnology company focused on developing disease-modifying therapies to stop or reverse the progression of neurodegenerative diseases.


You may also be interested in these: